Zimmer Biomet (ZBH)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$87.56-2.07%
Close 2026-07-08 · 1-day change
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on healthcare. The current thesis state is intact, as recent financial performance remains strong compared to industry peers.
The market seems to have a neutral valuation of ZBH, which is considered cheap compared to its peers. There is a slight expectations gap, indicating that the market may not fully account for potential upside in earnings.
Management has shown robust earnings quality, but there are concerns about revenue growth and EPS guidance, which are currently behind schedule. The near-term risk of missing earnings is low, but the company operates in a sector where peers have been missing expectations.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could positively impact ZBH. Conversely, if they start to miss expectations, it could negatively affect ZBH's momentum.
Overall, ZBH's performance is currently stable, but external sector factors will be crucial in determining its trajectory over the next few years. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read. However, there are growth headwinds that threaten it. The acquisition of Pacira's Iovera device could help expand product offerings.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Missing this target shows problems in operations. It might also hurt investor confidence.
Confirms:Q2 2026 earnings per share reported below $1.22.
Disproves:Q2 2026 earnings per share reported above $1.30.
Why it matters: This shows weak sales momentum. It raises worries about future growth.
Confirms:Q2 organic revenue growth is below 1.0%.
Disproves:Q2 organic revenue growth is above 3.0%.
Why it matters: An increase in EPS guidance would show stronger profit expectations. This could boost investor confidence.
Confirms:Management raises EPS guidance for the next quarter in the upcoming earnings call.
Disproves:Management keeps or lowers EPS guidance for the next quarter.
Why it matters: Updates about the CFO change show that financial management is stable. This helps build investor trust.
Confirms one read:A new CFO is announced. They have relevant experience and a positive vision for the company.
Confirms the other:No news about the CFO transition creates uncertainty.
Why it matters: Hitting this target shows good use of money. It also shows a promise to give value to shareholders.
Confirms:Share repurchases total $1 billion or more in 2026.
Disproves:Share repurchases total less than $500 million in 2026.
Why it matters: High adoption rates of new products can drive revenue growth and market share.
Confirms one read:New products achieve adoption rates above 20% in Q2.
Confirms the other:New products see adoption rates below 10% in Q2.
Why it matters: Updates on share buybacks show strong capital use. They also show confidence in the company.
Confirms:Share buybacks over $500 million will be completed by Q3 2026.
Disproves:No significant share buybacks reported by Q3 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: An increase in EPS guidance would signal strong financial health and confidence in future performance.
Confirms:Adjusted EPS guidance raised above $8.55.
Disproves:Adjusted EPS guidance remains at or below $8.40.